U.S. government-sponsored agency bonds US Government Corporations and Agencies Securities [Member] Undiscounted cash payment obligations Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Work in process Inventory, Work in Process, Gross Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Schedule of Lease Costs Lease, Cost [Table Text Block] Amounts invoiced as prepayments for product supply Contract With Customer, Liability, Revenue Invoiced As Prepayments For Product Supply, Current Contract With Customer, Liability, Revenue Invoiced As Prepayments For Product Supply, Current Schedule of Securities Classified as Cash, Cash Equivalents and Investments Cash, Cash Equivalents and Investments [Table Text Block] Cover [Abstract] Cover [Abstract] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Additional default interest rate (as percent) Debt Instrument, Interest Rate On Default, Percentage Percentage of additional default interest rate on the event of default. Board of directors Director [Member] Schedule of Undiscounted Cash Payment Obligations for Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] David Rosenbaum [Member] David Rosenbaum Schedule of Additional Details of Leases Schedule Of Additional Details Of Leases [Table Text Block] The tabular disclosure of additional details of the leases. Trading Symbol Trading Symbol All Trading Arrangements All Trading Arrangements [Member] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of Computation of Net Loss Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Cash paid for income taxes Income Taxes Paid, Net Common stock Common Class A [Member] XPHOZAH Product, XPHOZAH [Member] Product, XPHOZAH Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Accounts receivable Increase (Decrease) in Accounts Receivable Derivative [Table] Derivative [Table] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Issuance of common stock upon vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Schedule of Restricted Stock Units Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] LEASES Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Operating lease expense Operating Lease, Cost Lease costs Lease, Cost [Abstract] Copay and Returns Contract With Customer, Copay and Returns [Member] Contract With Customer, Copay and Returns Operating lease liability, net of current portion Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Other cost of revenue Product and Service, Other [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Revenue from Contract with Customer [Abstract] Non-cash royalty revenue related to the sale of future royalties Non-Cash Royalty Related To Sale Of Future Royalties Non-Cash Royalty Related To Sale Of Future Royalties Deferred revenue Beginning balance Ending balance Contract with Customer, Liability, Current Plan Name [Domain] Plan Name [Domain] Loan Agreement Loans Payable [Member] Other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Money market funds Money market funds Money Market Funds [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] After first anniversary through second anniversary of closing date Debt Instrument, Redemption, Period Two [Member] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] U.S. treasury securities US Treasury Securities [Member] Beginning balance Ending balance Contract With Customer, Gross To Net Sales Accruals Contract With Customer, Gross To Net Sales Accruals Plan Name [Axis] Plan Name [Axis] Fee receivable for reduction in royalty rate Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate Equity Components [Axis] Equity Components [Axis] Stock-based Compensation [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Award Timing Method Award Timing Method [Text Block] KKC Kyowa Kirin Co. Ltd [Member] Represents the information pertaining to Kyowa Kirin Co., Ltd. Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Fair Value Debt Securities, Available-for-Sale Loan agreement covenant, net product revenue as percentage of outstanding loan balance, minimum Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Gross product revenue Revenue, Product and Service Benchmark [Member] Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Remaining funding based on milestone achievement Remaining Funding Based On Conditional Milestone Achievement Remaining Funding Based On Conditional Milestone Achievement Total operating expenses Costs and Expenses Potential commercialization milestones Collaborative Arrangement, Potential Commercialization Milestones Collaborative Arrangement, Potential Commercialization Milestones Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional paid-in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Supplementary disclosure of non-cash activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Unrealized losses on available-for-sale securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Cash and short-term investments Cash and short-term investments Investments and Cash Loan agreement, covenant, cash and cash equivalents as percentage of outstanding loan balance, calculation period (in months) Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Contingent liabilities Loss Contingency Accrual Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Issuance of common stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Thereafter Lessee, Operating Lease, Liability, To Be Paid, After Year Three Lessee, Operating Lease, Liability, To Be Paid, After Year Three CASH, CASH EQUIVALENTS AND INVESTMENTS Cash, Cash Equivalents, and Short-Term Investments [Text Block] Closing fee Debt Instrument, Closing Fee Amount Debt Instrument, Closing Fee Amount Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Total cash equivalents and investments, Gross Unrealized Losses Cash Cash Equivalents And Investments Gross Unrealized Losses Cash, cash equivalents and investments gross unrealized losses. Unrecognized Compensation Expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Percentage of royalty revenue Percentage of Royalty Revenue Represents percentage of royalty revenue. Current assets: Assets, Current [Abstract] INVENTORY Inventory Disclosure [Text Block] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Products and Services [Domain] Product and Service [Domain] Stock option grants Options to purchase common stock Share-Based Payment Arrangement, Option [Member] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Derivative liabilities for exit fee Exit Fee derivative liability Derivative Financial Instruments, Liabilities [Member] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Cardinal Health Cardinal Health [Member] Cardinal Health Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Decrease for revenue recognized for product supply Contract With Customer, Liability, Revenue Recognized Cash Not Received, Current Contract With Customer, Liability, Revenue Recognized Cash Not Received, Current Licensing revenue License License [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Security Exchange Name Security Exchange Name Floating per annum rate (as percent) Debt Instrument, Basis Spread on Variable Rate Award Type [Axis] Award Type [Axis] Inventory Inventory Inventory, Gross Options exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Transaction costs Contract With Customer, Liability, Transaction Costs Contract With Customer, Liability, Transaction Costs Number of RSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property and equipment, net Property, Plant and Equipment, Net Gross To Net Sales Accrual And Reserve Classification [Axis] Gross To Net Sales Accrual And Reserve Classification [Axis] Gross To Net Sales Accrual And Reserve Classification IBSRELA Product, IBSRELA [Member] Product, IBSRELA Total liabilities Liabilities Options exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Comprehensive loss: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Purchase price (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award, Purchased Price of Share Represents the purchase price per share of shares issued to employees under the plan. AmerisourceBergen Drug Corporation AmerisourceBergen Drug Corporation [Member] AmerisourceBergen Drug Corporation Potential development and commercialization milestones Collaborative Arrangement, Potential Development And Commercialization Milestones Represents the amount of future development and commercialization milestone under collaborative arrangements. Current portion of operating lease liability Current portion of lease liabilities Less: Current portion of operating lease liability Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Common Stock, Shares, Issued Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Concentration risk (as percent) Concentration Risk, Percentage Derivative Liability Derivative Liability Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Issuance of common stock upon exercise of options (in shares) Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted-Average Exercise Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Research and development Research and Development Expense [Member] Gross To Net Sales Accrual And Reserve Classification [Domain] Gross To Net Sales Accrual And Reserve Classification [Domain] Gross To Net Sales Accrual And Reserve Classification [Domain] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Cash Cash [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Shares used in computing net loss per share - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Agreed amount for exit fee upon occurrence of certain conditions Agreed amount for exit fee upon change of control or regulatory approval Derivative Liability, Notional Amount MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Long-term debt Loans Payable, Noncurrent Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] 2022 Term Loan Term Loan 2022 [Member] Term Loan 2022 Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent COLLABORATION AND LICENSING AGREEMENTS Collaborative Arrangement Disclosure [Text Block] Litigation Case [Axis] Litigation Case [Axis] Interest expense Interest Expense, Nonoperating Additional details Lessee, Operating Lease, Description [Abstract] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Selling, general and administrative Selling, General and Administrative Expense Recurring Fair Value, Recurring [Member] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Product sales Product [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Sale of Stock [Domain] Sale of Stock [Domain] Long-term debt Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Assets Assets [Abstract] Document Type Document Type Closing fee percentage Line of Credit Facility, Commitment Fee Percentage Derivative Contract [Domain] Derivative Contract [Domain] Prepaid commercial manufacturing Prepaid Commercial Manufacturing, Current Prepaid Commercial Manufacturing, Current Commercial paper Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] After second anniversary to maturity date Debt Instrument, Redemption, Period Three [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Schedule of Deferred Revenue Balances Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Right-of-use assets and lease liabilities Assets and Liabilities, Lessee [Abstract] Non-cash royalty revenue Revenue to be received Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Accounts payable Accounts Payable, Current Revenues: Revenues [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Prepayment premium (as percent) Debt Instrument, Prepayment Fee, Percentage The percentage of fee payable on prepayment of debt. Short-term securities, contractual maturities maximum (in years) Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum Amounts invoiced as prepayments for product supply Contract With Customer, Liability, Revenue Invoiced As Prepayments For Product Supply, Noncurrent Contract With Customer, Liability, Revenue Invoiced As Prepayments For Product Supply, Noncurrent Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Imputed interest expenses Lessee, Operating Lease, Liability, Undiscounted Excess Amount Threshold percentage of net sales for tiered royalties Threshold Percentage of Sales For Tiered Royalties Represents the threshold percentage of net sales for tiered royalties. PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Proceeds from 2022 Loan Agreement, net of issuance costs Proceeds from Issuance of Secured Debt Schedule of Anti-Dilutive Securities Not Considered in Diluted Net Loss Per Common Share Calculation Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Schedule of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block] Non-PEO NEO Non-PEO NEO [Member] Title of Individual [Axis] Title and Position [Axis] Advance Royalties [Abstract] Accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities Additional Paid-In Capital Additional Paid-in Capital [Member] 2023 Open Market Sales Agreement Open Market Sales Agreement 2023, At The Market Offering [Member] Open Market Sales Agreement 2023, At The Market Offering Exit fee, term (in years) Loan Agreement, Exit Fee, Term Loan Agreement, Exit Fee, Term Award Timing Predetermined Award Timing Predetermined [Flag] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Net loss per share of common stock - diluted (in dollars per share) Earnings Per Share, Diluted Title of Individual [Domain] Title and Position [Domain] Royalty payments and commercial milestone payments Increase (Decrease) in Royalties Payable Counterparty Name [Domain] Counterparty Name [Domain] Non-cash lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Name Measure Name Cost of goods sold: Cost of Goods and Services Sold [Abstract] Entity Interactive Data Current Entity Interactive Data Current Fosun Pharma Shanghai Fosun Pharmaceutical Industrial Development [Member] Represents Shanghai Fosun Pharmaceutical Industrial Development. Reclassify amounts to be recognized in the next twelve months Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Knight Agreement License Agreement Development Commercialization Distribution In Canada [Member] Agreement for the development, commercialization and distribution fo tenapanor in Canada. The Knight Agreement. Number of segments Number of Operating Segments Customer [Axis] Customer [Axis] Schedule of Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Additional uncommitted capital Line Of Credit Facility, Accordion Feature, Additional Uncommitted Capital Line Of Credit Facility, Accordion Feature, Additional Uncommitted Capital Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Asset-backed securities Asset-backed securities Asset-Backed Securities [Member] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Schedule of Noncurrent Inventory Schedule of Inventory, Noncurrent [Table Text Block] Provision for income taxes Income Tax Expense (Benefit) Interest rate (as percent) Debt Instrument, Interest Rate, Stated Percentage Short-term investments Debt Securities, Available-for-Sale, Current ESPP ESPP shares issuable Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Supplementary disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Average Remaining Vesting Period (Years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Weighted-average sales price per share (in dollars per share) Sale Of Stock, Weighted-Average Price Per Share Sale Of Stock, Weighted-Average Price Per Share Other income, net Nonoperating Income (Expense) Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Aggregate cost of revenue recognized Cost Of Revenue, Aggregate Amount Recognized Cost of revenue, aggregate amount recognized. AZ Termination Agreement AstraZeneca Termination Agreement [Member] AstraZeneca Termination Agreement Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Variable Rate [Domain] Variable Rate [Domain] Total liabilities and stockholders’ equity Liabilities and Equity Other, net Other Operating Activities, Cash Flow Statement All Adjustments to Compensation All Adjustments to Compensation [Member] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accrued compensation and benefits Employee-related Liabilities, Current Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets DERIVATIVE LIABILITIES Derivative Instruments and Hedging Activities Disclosure [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Future Debt Payment Obligations Schedule of Maturities of Long-Term Debt [Table Text Block] ORGANIZATION AND BASIS OF PRESENTATION​ Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Right-of-use assets obtained in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Percentage of non-royalty revenue Percentage Of Non-Royalty Revenue Represents percentage of non-royalty revenue. Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Options forfeited or canceled (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Total Inventory, Net U.S. government-sponsored agency bonds US Government Agencies Debt Securities [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Operating expenses: Operating Expenses [Abstract] Product supply revenue Product Supply Revenue [Member] Product Supply Revenue Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Robert Blanks [Member] Robert Blanks Exit fee (as percent) Exit Fee, Percentage Exit Fee, Percentage Outstanding balance, beginning (in dollars per share) Outstanding balance, ending (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Total of gross proceeds Equity Sales Agreement, Proceeds From Shares Issued Since Inception Equity Sales Agreement, Proceeds From Shares Issued Since Inception Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Number of lawsuits Loss Contingency, New Claims Filed, Number Less: Unamortized discount and debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Commission on sale of stock per agreement (as percent) Stock Issuance Cost, Commission, Percent Stock Issuance Cost, Commission, Percent Restatement Determination Date Restatement Determination Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Adoption Date Trading Arrangement Adoption Date Deferred revenue, non-current Beginning balance Ending balance Contract with Customer, Liability, Noncurrent Number of defendants Loss Contingency, Number of Defendants Options outstanding balance, beginning (in dollars per share) Options outstanding balance, ending (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Right-of-use assets Right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Options outstanding balance, beginning (in shares) Options outstanding balance, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Final fee due upon maturity, acceleration, prepayment, or termination (as percent) Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage Derivative Instrument [Axis] Derivative Instrument [Axis] AstraZeneca Astrazeneca [Member] Represents information pertaining to AstraZeneca. Principal outstanding Total repayment obligations Long-Term Debt, Gross Exercise Price Award Exercise Price Proceeds from milestone payments Revenue, Remaining Performance Obligation, Variable Consideration Amount Revenue, Remaining Performance Obligation, Variable Consideration Amount NET LOSS PER SHARE Earnings Per Share [Text Block] Number of payment tranches for fee receivable for reduction in royalty rate Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches Accrued compensation and benefits Increase (Decrease) in Employee Related Liabilities Arrangement Duration Trading Arrangement Duration Issuance of common stock under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock upon exercise of options Stock Issued During Period, Value, Stock Options Exercised Stockholders’ equity: Equity, Attributable to Parent [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Additional committed capital Line Of Credit Facility, Accordion Feature, Additional Committed Capital Line Of Credit Facility, Accordion Feature, Additional Committed Capital Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] 2018 Term Loan Term Loan 2018 [Member] Term Loan 2018 All Individuals All Individuals [Member] PEO PEO [Member] Fosun Agreement License Agreement Development Commercialization Distribution In China [Member] Agreement for the development, commercialization and distribution of tenapanor in China. The Fosun Agreement. DEFERRED ROYALTY OBLIGATION RELATED TO THE SALE OF FUTURE ROYALTIES Asset Retirement Obligation Disclosure [Text Block] Variable Rate [Axis] Variable Rate [Axis] Non-Current Change In Contract With Customer Liability, Noncurrent, Rollforward [Roll Forward] Change In Contract With Customer Liability, Noncurrent, Rollforward Name Trading Arrangement, Individual Name Schedule of Chargebacks, Discounts and Reserve Balances Schedule Of Gross To Net Sales Accruals [Table Text Block] Schedule Of Gross To Net Sales Accruals Term Loan A Term Loan 2022 A [Member] Term Loan 2022 A Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Exit fee, net product revenue threshold Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum 2017 KKC Agreement License Agreement Development Commercialization Distribution In Japan [Member] Agreement for the development, commercialization and distribution of tenapanor in Japan. The 2017 KKC Agreement. Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Proceeds from issuance of common stock under equity incentive and stock purchase plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Schedule of Revenue from Customers as a Percentage of Total Product Revenue, Net Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Assets: Assets, Fair Value Disclosure [Abstract] Issuance of common stock for services Stock Issued Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding 2021 Open Market Sales Agreement Open Market Sales Agreement 2021, At The Market Offering [Member] Open Market Sales Agreement 2021, At The Market Offering Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Liability Class [Axis] Liability Class [Axis] Cash and cash equivalents: Cash and Cash Equivalents, at Carrying Value [Abstract] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Potential development milestones Collaborative Arrangement, Potential Development Milestones Collaborative Arrangement, Potential Development Milestones Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Allowance for credit loss on available for-sale debt securities Debt Securities, Available-for-Sale, Allowance for Credit Loss Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] PEO Total Compensation Amount PEO Total Compensation Amount Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Provisions Contract With Customer, Gross To Net Sales, Provisions Contract With Customer, Gross To Net Sales, Provisions Proceeds from maturities and redemptions of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Issuance of common stock for services Stock Issued During Period, Value, Issued for Services Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock Common Stock [Member] Measure: Measure [Axis] Asset Class [Domain] Asset Class [Domain] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Changes in Fair Value of Derivative Liability Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Issuance of common stock in at the market offering (in shares) Stock Issued During Period, Shares, New Issues Prior to first anniversary of closing date Debt Instrument, Redemption, Period One [Member] Investment in continuous unrealized loss position for more than one year Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Entity Emerging Growth Company Entity Emerging Growth Company Liabilities, fair value Liabilities, Fair Value Disclosure Entity Central Index Key Entity Central Index Key Healthcare royalty partners IV, L.P HealthCare Royalty Partners IV, L.P [Member] HealthCare Royalty Partners IV, L.P Schedule of Current Inventory Schedule of Inventory, Current [Table Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Rebates, Wholesaler and GPO Fees Contract With Customer, Rebates, Wholesaler And GPO Fees [Member] Contract With Customer, Rebates, Wholesaler And GPO Fees STOCKHOLDERS’ EQUITY Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Changes in estimated fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Counterparty Name [Axis] Counterparty Name [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Knight Knight Therapeutics Inc [Member] Represents information pertaining to Knight Therapeutics Inc. Proceeds from royalty payments Proceeds From Royalty Payments Proceeds From Royalty Payments City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Strezsak v. Ardelyx, Inc. Strezsak Versus Ardelyx, Inc. [Member] Strezsak Versus Ardelyx, Inc. Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Purchases of investments Payments to Acquire Short-Term Investments Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Level 1 Fair Value, Inputs, Level 1 [Member] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Total current assets Assets, Current BioRidge Pharma, LLC BioRidge Pharma, LLC [Member] BioRidge Pharma, LLC Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Accrued and other liabilities Increase (Decrease) in Accrued Liabilities Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Collaboration and Licensing Agreements Collaboration and Licensing Agreements n/a Weighted-Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Class of Stock [Domain] Class of Stock [Domain] Less: Current portion of long-term debt Loans Payable, Current Inventory Increase (Decrease) in Inventories Current Change In Contract With Customer Liability, Current, Rollforward [Roll Forward] Change In Contract With Customer Liability, Current, Rollforward Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Total operating lease liabilities Operating Lease, Liability Prepaid commercial manufacturing, non-current Prepaid Commercial Manufacturing, Non Current Prepaid Commercial Manufacturing, Non Current Less: Unaccreted value of final fee Debt Instrument, Fee Amount Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Floor Rate Secured Overnight Financing Rate (SOFR) Floor Rate [Member] Secured Overnight Financing Rate (SOFR) Floor Rate Deferred royalty obligation related to the sale of future royalties Deferred Royalty Obligation, Noncurrent Deferred Royalty Obligation, Noncurrent Discounts and Chargebacks Contract With Customer, Discounts And Chargebacks [Member] Contract With Customer, Discounts And Chargebacks Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Term Loan C Term Loan 2022 C [Member] Term Loan 2022 C Depreciation and amortization expense Depreciation, Depletion and Amortization Fair Value as of Grant Date Award Grant Date Fair Value Customer Customer Concentration Risk [Member] Reclassify amounts to be recognized in the next twelve months Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months Level 2 Fair Value, Inputs, Level 2 [Member] BORROWING Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Decrease for revenue recognized for product supply Contract With Customer, Liability, Revenue Recognized Cash Not Received, Noncurrent Contract With Customer, Liability, Revenue Recognized Cash Not Received, Noncurrent Maximum potential payment per agreement Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum Upfront license fees Collaboration And Licensing Agreements, Upfront License Fees Collaboration And Licensing Agreements, Upfront License Fees Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Term loan face amount Debt Instrument, Face Amount Schedule of Revenue Disaggregation of Revenue [Table Text Block] Issuance of common stock in at the market offering Stock Issued During Period, Value, New Issues Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Stock-Based Compensation Expense Recognized Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, $0.0001 par value; 500,000,000 shares authorized; 235,401,398 and 232,453,190 shares issued and outstanding as of June 30, 2024 and December 31, 2023 Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Future obligation upon loan funding or other events Loan Agreement, Future Obligation Upon Funding Or Other Events Loan Agreement, Future Obligation Upon Funding Or Other Events Cash and cash equivalents Fair Value Cash and Cash Equivalents, at Carrying Value Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] U.S. treasury securities US Treasury Notes Securities [Member] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Raw materials Inventory, Raw Materials, Gross Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Credits/payments Contract With Customer, Gross To Credits Or Deductions Issued Contract With Customer, Gross To Credits Or Deductions Issued Finished goods Inventory, Finished Goods, Gross Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Net loss per share of common stock - basic (in dollars per share) Earnings Per Share, Basic Accounts payable Increase (Decrease) in Accounts Payable Proceeds from ESPP Proceeds from Stock Plans Proceeds from issuance of common stock in at the market offering, net of issuance costs Proceeds from Issuance of Common Stock Cash paid for operating lease Operating Lease, Payments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Total cash equivalents and investments, Gross Unrealized Gains Cash Cash Equivalents And Investments Gross Unrealized Gains Cash, cash equivalents and investments gross unrealized gains. Amortization, effective interest rate (as percent) Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Loan agreement covenant, cash and cash equivalents as percentage of outstanding loan balance, minimum Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum Proceeds from the sale of future royalties, net of issuance costs Proceeds from Debt, Net of Issuance Costs Prepaid commercial manufacturing Prepaid Commercial Manufacturing Prepaid Commercial Manufacturing Prepaid commercial manufacturing Increase (Decrease) In Prepaid Commercial Manufacturing Expense Increase (Decrease) In Prepaid Commercial Manufacturing Expense Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total assets Assets Total cost of goods sold Cost of Goods and Services Sold Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Term Loan B Term Loan 2022 B [Member] Term Loan 2022 B Justin Renz [Member] Justin Renz Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Non-cash royalty revenue related to the sale of future royalties Non-Cash Royalty Related To Sale of Future Royalties [Member] Non-Cash Royalty Related To Sale of Future Royalties Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 14) Commitments and Contingencies Termination Date Trading Arrangement Termination Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two EQUITY INCENTIVE PLANS​ Share-Based Payment Arrangement [Text Block] Total cash equivalents and investments, Amortized Cost Investments And Cash, Amortized Cost Investments And Cash, Amortized Cost Entity Address, City or Town Entity Address, City or Town Issuance of common stock for services (in shares) Stock Issued During Period, Shares, Issued for Services Debt Instrument [Axis] Debt Instrument [Axis] McKesson Corporation McKesson Corporation [Member] McKesson Corporation Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Go v. Raab Go Versus Raab [Member] Go Versus Raab Stock-based compensation expense Share-Based Payment Arrangement, Expense Net loss Net loss Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Non-cash interest expense Amortization of Debt Discount (Premium) Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Short-term investments: Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Entity File Number Entity File Number Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Gross-to-net sales accruals and reserves Contract With Customer, Gross To Net Sales Accrual [Roll Forward] Contract With Customer, Gross To Net Sales Accrual Liabilities: Liabilities, Fair Value Disclosure [Abstract] REVENUE Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Entity Address, Address Line Two Entity Address, Address Line Two Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Assets, fair value Assets, Fair Value Disclosure Name Forgone Recovery, Individual Name Remainder of 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Weighted-average remaining life (years) Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Term Loan D Term Loan 2022 D [Member] Term Loan 2022 D Total undiscounted operating lease payments Lessee, Operating Lease, Liability, to be Paid Outstanding balance, beginning (in shares) Outstanding balance, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Deferred revenue Increase (Decrease) in Deferred Revenue Asset Class [Axis] Asset Class [Axis] Insider Trading Arrangements [Line Items] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Cost of revenue Cost of Revenue 2018 Exit Fee Exit Fee 2018 [Member] Exit Fee 2018 Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Non-cash interest expense related to the sale of future royalties Non-cash interest expense related to the sale of future royalties Non-Cash Interest Expense Related To Sale Of Royalties Non-Cash Interest Expense Related To Sale Of Royalties Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Litigation Case [Domain] Litigation Case [Domain] Customer [Domain] Customer [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] 2022 Exit Fee Exit Fee 2022 [Member] Exit Fee 2022 Shares used in computing net loss per share - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Inventory, non-current Inventory, non-current Inventory, Noncurrent Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] RSU grants Restricted stock units Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Options forfeited or canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Maximum aggregate offering price Maximum Aggregate Offering Price Amount of maximum aggregate offering price. Entity Filer Category Entity Filer Category Payment to be received Revenue, Remaining Performance Obligation, Amount Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Contingencies [Line Items] Loss Contingencies [Line Items] Company Selected Measure Name Company Selected Measure Name Upfront payment received Proceeds from License Fees Received